DNA Link Inc (127120) - Total Assets
Based on the latest financial reports, DNA Link Inc (127120) holds total assets worth ₩123.04 Billion KRW (≈ $83.38 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See DNA Link Inc shareholders equity for net asset value and shareholders' equity analysis.
DNA Link Inc - Total Assets Trend (2011–2025)
This chart illustrates how DNA Link Inc's total assets have evolved over time, based on quarterly financial data.
DNA Link Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
DNA Link Inc's total assets of ₩123.04 Billion consist of 44.7% current assets and 55.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 32.9% |
| Accounts Receivable | ₩2.47 Billion | 2.0% |
| Inventory | ₩4.85 Billion | 3.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩205.69 Million | 0.2% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how DNA Link Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 127120 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DNA Link Inc's current assets represent 44.7% of total assets in 2025, a decrease from 53.8% in 2011.
- Cash Position: Cash and equivalents constituted 32.9% of total assets in 2025, up from 16.3% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 3.9% of total assets.
DNA Link Inc Competitors by Total Assets
Key competitors of DNA Link Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $1.30 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.48 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
DNA Link Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.14 | 0.53 | 3.37 |
| Quick Ratio | 1.04 | 0.43 | 2.97 |
| Cash Ratio | 0.00 | 0.17 | 0.00 |
| Working Capital | ₩6.92 Billion | ₩-12.87 Billion | ₩28.65 Billion |
DNA Link Inc - Advanced Valuation Insights
This section examines the relationship between DNA Link Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 17.23 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 126.2% |
| Total Assets | ₩123.04 Billion |
| Market Capitalization | $897.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values DNA Link Inc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: DNA Link Inc's assets grew by 126.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for DNA Link Inc (2011–2025)
The table below shows the annual total assets of DNA Link Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩123.04 Billion ≈ $83.38 Million |
+126.23% |
| 2024-12-31 | ₩54.39 Billion ≈ $36.86 Million |
+40.32% |
| 2023-12-31 | ₩38.76 Billion ≈ $26.27 Million |
-10.92% |
| 2022-12-31 | ₩43.51 Billion ≈ $29.48 Million |
+6.07% |
| 2021-12-31 | ₩41.02 Billion ≈ $27.80 Million |
-21.94% |
| 2020-12-31 | ₩52.54 Billion ≈ $35.61 Million |
+102.87% |
| 2019-12-31 | ₩25.90 Billion ≈ $17.55 Million |
-26.14% |
| 2018-12-31 | ₩35.07 Billion ≈ $23.76 Million |
+39.89% |
| 2017-12-31 | ₩25.07 Billion ≈ $16.99 Million |
-3.07% |
| 2016-12-31 | ₩25.86 Billion ≈ $17.53 Million |
-20.99% |
| 2015-12-31 | ₩32.73 Billion ≈ $22.18 Million |
+59.84% |
| 2014-12-31 | ₩20.48 Billion ≈ $13.88 Million |
-31.82% |
| 2012-12-31 | ₩30.03 Billion ≈ $20.35 Million |
+46.56% |
| 2011-12-31 | ₩20.49 Billion ≈ $13.89 Million |
-- |
About DNA Link Inc
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray… Read more